selpercatinib data underscore value of precision medicine in ret-driven lung cancer
Published 3 years ago • 467 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
2:52
updated overall efficacy and safety of selpercatinib in patients with ret fusion nsclc
-
1:45
targeting ret in lung cancer
-
0:52
genomic testing is necessary in non-small cell lung cancer
-
2:58
[lung] effect of selpercatinib for ret-positive patients
-
3:58
highlights on selpercatinib in ret fusion-positive nsclc: the libretto-431 study
-
3:48
ctcl overview (chapter 1)
-
6:52
safety and toxicity of selpercatinib versus pralsetinib - targeted therapies in lung cancer 2023
-
59:30
lung biopsies with 18g full core instruments: is it safe and efficacious?
-
8:43
selpercatinib and pralsetinib in ret disease - lung cancer video library
-
1:48
selpercatinib induced durable efficacy in ret fusion-positive nsclc
-
6:42
selpercatinib benefit, with or without pembro, in first-line advanced ret fusion-positive nsclc
-
3:48
highlights on selpercatinib in ret-mutant medullary thyroid cancer: the libretto-531 study
-
4:27
[lung] selpercatinib is also effective against brain metastasis.
-
1:06
optimizing precision medicine in nsclc
-
4:05
arrow: precision targeted therapy with pralsetinib for ret fusion tumors
-
16:38
precision medicine in lung cancer: where are we today? a medical oncologist perspective
-
7:02
fda approval of selpercatinib for ret fusion positive nsclc and thyroid cancers
-
1:51
cdsco panel seeks data for eli lilly’s cancer drug selpercatinib
-
7:34
intracranial activity of selpercatinib in ret fusion positive nsclc